▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

SpringWorks Therapeutics (NASDAQ: SWTX)

Some price data may be temporarily unavailable.

SpringWorks Therapeutics Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
SWTX	+24.74%	+13.56%	+2.58%	+108%
S&P	+13.41%	+100.62%	+14.92%	+109%

SpringWorks Therapeutics Company Info

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, BGB-3245 (RAF Fusion and Dimer Inhibitor), SW-682 (TEAD Inhibitor), and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

News & Analysis

Featured Article

What Company Will Eli Lilly Buy Next?

Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.

David Haen | Jan 23, 2020

Featured Article

Here's Why SpringWorks Therapeutics Climbed 69% in December

The stock climbed after investors saw encouraging signs from a similar program.

Cory Renauer | Jan 12, 2020

Are There Good Investments Among 2019's Biotech IPOs?

David Haen | Oct 2, 2019

Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services